Growth Metrics

Eli Lilly (LLY) Non-Current Assets (2016 - 2026)

Eli Lilly filings provide 18 years of Non-Current Assets readings, the most recent being $61.7 billion for Q1 2026.

  • On a quarterly basis, Non-Current Assets rose 28.29% to $61.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $222.5 billion, a 23.65% increase, with the full-year FY2025 number at $56.8 billion, up 23.65% from a year prior.
  • Non-Current Assets hit $61.7 billion in Q1 2026 for Eli Lilly, up from $56.8 billion in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $61.7 billion in Q1 2026 to a low of $29.8 billion in Q3 2022.
  • Median Non-Current Assets over the past 5 years was $38.8 billion (2024), compared with a mean of $41.3 billion.
  • Biggest five-year swings in Non-Current Assets: dropped 1.85% in 2022 and later rose 28.29% in 2026.
  • Eli Lilly's Non-Current Assets stood at $31.5 billion in 2022, then rose by 21.69% to $38.3 billion in 2023, then grew by 20.1% to $46.0 billion in 2024, then increased by 23.65% to $56.8 billion in 2025, then rose by 8.61% to $61.7 billion in 2026.
  • The last three reported values for Non-Current Assets were $61.7 billion (Q1 2026), $56.8 billion (Q4 2025), and $52.9 billion (Q3 2025) per Business Quant data.